Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;10(5):2986-2990.
doi: 10.3892/ol.2015.3667. Epub 2015 Sep 2.

Cyclin G2: A novel independent prognostic marker in pancreatic cancer

Shinichiro Hasegawa  1 , Hiroaki Nagano  2 , Masamitsu Konno  3 , Hidetoshi Eguchi  2 , Akira Tomokuni  2 , Yoshito Tomimaru  2 , Hiroshi Wada  2 , Naoki Hama  2 , Koichi Kawamoto  2 , Shogo Kobayashi  2 , Shigeru Marubashi  2 , Naohiro Nishida  3 , Jun Koseki  4 , Noriko Gotoh  5 , Shouichi Ohno  6 , Norikazu Yabuta  6 , Hiroshi Nojima  6 , Masaki Mori  2 , Yuichiro Doki  2 , Hideshi Ishii  7
Affiliations

Cyclin G2: A novel independent prognostic marker in pancreatic cancer

Shinichiro Hasegawa et al. Oncol Lett. 2015 Nov.

Abstract

Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

Keywords: cyclin G2; immunohistochemical staining; overall survival; pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Expression levels of cyclin G2 in the normal section of pancreatic tissues demonstrated by immunohistochemical staining. (A) Normal pancreatic ductal cells and (B) acinar cells that were used as positive controls.
Figure 2.
Figure 2.
Cyclin G2 (CCNG2) expression in primary pancreatic cancer samples, observed by immunohistochemical staining. CCNG2-positive cases demonstrated a (A) diffused or (B) spotted nuclear pattern; by contrast, CCNG2-negative cases exhibited a (C) cytoplasmic pattern (no staining in the nucleus) or (D) negative pattern (no staining in the nucleus or cytoplasm).
Figure 3.
Figure 3.
Overall survival rate of 36 patients who underwent complete surgical resection for pancreatic cancer with clear histological margins, according to cyclin G2 expression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. doi: 10.1056/NEJMoa032295. - DOI - PubMed
    1. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. doi: 10.1001/jama.2013.279201. - DOI - PubMed
    1. Eguchi H, Nagano H, Tanemura M, Takeda Y, Marubashi S, Kobayashi S, Kawamoto K, Wada H, Hama N, Akita H, et al. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Hepatogastroenterology. 2013;60:904–911. - PubMed
    1. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–3502. doi: 10.1200/JCO.2007.15.8634. - DOI - PubMed